We are pleased to announce that the following officers were elected at our company's Fourth Annual (2024FY) General Shareholders Meeting and have officially assumed their respective positions. To strengthen our management structure, Kosuke Matsunaga has been appointed as Representative Director, effective immediately.
Moving forward, our executive team remains committed to the advancement of innovative cancer treatments. We sincerely appreciate your continued support.
Newly Elected and Continuing Board Members:
President & CEO: Kosuke Matsunaga (New Appointment)
Chairman of the Board: Kazuto Takesako (Continuing)
Senior Vice President, COO: Masanobu Kimura (Continuing)
Director (Outside): Kei Fujioka (Continuing, Representative Director of Takt Pharma Co., Ltd.)
Auditor: Takashi Mitsuguchi (New Appointment, DBJ Capital)
Kosuke Matsunaga was born in 1981 and graduated from the University of Massachusetts. He has an extensive background in the pharmaceutical industry, with experience at leading companies:
2007: ABsize
2012: Takeda Pharmaceutical
2020: AbbVie
2022: Reborna Biosciences
With this new leadership structure, we are confident in our ability to drive the company’s growth and contribute to the development of groundbreaking treatments.
Thank you for your continued trust and support.
Yorumlar